Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
British Journal of Cancer
|
December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 24, 2022
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
JCO Precision Oncology
|
July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes
Sriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
The Lancet. Oncology
|
February 6, 2025
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
The Lancet. Oncology
|
March 17, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, et al.
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Cell
|
May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistance
Ben Sang, Ling Feng Ye, Zheng Fu, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
British Journal of Cancer
|
December 9, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
Rebecca S Kristeleit, Yvette Drew, Amit M Oza, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 24, 2022
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
JCO Precision Oncology
|
July 9, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes
Sriram Anbil, Nicholas J Seewald, E Gabriela Chiorean, et al.
The Lancet. Oncology
|
February 6, 2025
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
The Lancet. Oncology
|
March 17, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, et al.
Gynecologic Oncology
|
October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Cell
|
May 7, 2026
Disrupted molecular glue complex drives RAS inhibitor resistance
Ben Sang, Ling Feng Ye, Zheng Fu, et al.
Page
of 6